Simcere Pharmaceutical Group Limited (2096.HK)

HKD 8.99

(2.63%)

Operating Income Summary of Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited's latest annual operating income in 2023 was 711.8 Million CNY , down -17.47% from previous year.
Simcere Pharmaceutical Group Limited's latest quarterly operating income in 2024 Q2 was 246.08 Million CNY , down 0.0% from previous quarter.
Simcere Pharmaceutical Group Limited reported an annual operating income of 862.5 Million CNY in 2022, up 25.38% from previous year.
Simcere Pharmaceutical Group Limited reported an annual operating income of 687.9 Million CNY in 2021, up 21.61% from previous year.
Simcere Pharmaceutical Group Limited reported a quarterly operating income of 246.08 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Simcere Pharmaceutical Group Limited reported a quarterly operating income of -800.1 Million CNY for 2023 Q4, down -554.63% from previous quarter.

Annual Operating Income Chart of Simcere Pharmaceutical Group Limited (2023 - 2012)

Historical Annual Operating Income of Simcere Pharmaceutical Group Limited (2023 - 2012)

Year	Operating Income	Operating Income Growth
2023	711.8 Million CNY	-17.47%
2022	862.5 Million CNY	25.38%
2021	687.9 Million CNY	21.61%
2020	565.66 Million CNY	-51.71%
2019	1.17 Billion CNY	24.35%
2018	941.94 Million CNY	77.53%
2017	530.57 Million CNY	0.0%
2012	96.36 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	246.08 Million CNY	130.76%
2024 Q2	246.08 Million CNY	0.0%
2023 Q4	-800.1 Million CNY	-554.63%
2023 FY	711.8 Million CNY	-17.47%
2023 Q1	179.42 Million CNY	58.61%
2023 Q2	179.42 Million CNY	0.0%
2023 Q3	175.99 Million CNY	-1.92%
2022 Q1	190.04 Million CNY	126.61%
2022 FY	862.5 Million CNY	25.38%
2022 Q4	113.12 Million CNY	0.0%
2022 Q3	113.12 Million CNY	-40.47%
2022 Q2	190.04 Million CNY	0.0%
2021 Q3	83.86 Million CNY	155.68%
2021 FY	687.9 Million CNY	21.61%
2021 Q1	32.8 Million CNY	-77.81%
2021 Q2	32.8 Million CNY	0.0%
2021 Q4	83.86 Million CNY	0.0%
2020 Q4	147.8 Million CNY	0.0%
2020 FY	565.66 Million CNY	-51.71%
2020 Q1	152.14 Million CNY	-46.99%
2020 Q2	152.14 Million CNY	0.0%
2020 Q3	147.8 Million CNY	-2.85%
2019 Q2	290.65 Million CNY	0.0%
2019 Q1	290.65 Million CNY	0.0%
2019 Q4	287.02 Million CNY	0.0%
2019 FY	1.17 Billion CNY	24.35%
2019 Q3	287.02 Million CNY	-1.25%
2018 FY	941.94 Million CNY	77.53%
2017 FY	530.57 Million CNY	0.0%
2013 Q1	50.18 Million CNY	335.03%
2013 Q2	10.71 Million CNY	-78.65%
2013 Q3	-181 Thousand CNY	-101.69%
2012 Q1	53.3 Million CNY	0.0%
2012 Q2	50.71 Million CNY	-4.86%
2012 Q3	1.68 Million CNY	-96.68%
2012 Q4	-21.35 Million CNY	-1367.93%
2012 FY	96.36 Million CNY	0.0%

Peer Operating Income Comparison of Simcere Pharmaceutical Group Limited

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	-950.351%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	20.731%